Stem Cells Inc, (STEM), developer of stem cell-based treatments for spinal injury, is up for the second day in a row Friday in pre-market trading, after it closed Thursday at $1.96, a 19% gain on the day. The gains came after the company announced that it will be presenting data from its Phase I/II clinical trial on Monday, Sept. 3 at the International Spinal Cord Society and will hold a conference call the following day. Trading volume Thursday was three times its 3-month average. The presentation will include interim data from the study`s first cohort, which has three partially paralyzed patients being treated with STEM`s proprietary HuCNS-SC cells. Researchers are looking for efficacy - measured by improvement in motor function, sensation, and bladder control - and safety in the first of three planned cohorts, each with more mild paralysis than the previous. Share price is likely to remain strong on Friday and into the meeting, as most analysts expect some positive results from the trial. If Monday`s data looks good for STEM, shares may climb higher on momentum, however, negative results will have disastrous effects on the stock. STEM is up 140% in 2012.
Click here to see this article at PropThink.com.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://www.propthink.com.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE HUG#1637958
View original post here:
PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday